- Wednesday, September 1, 2021 @ 12:00 am
- Company founded and led by a world-class leadership team with outstanding expertise in the biopharmaceutical industry, in pharmaceutical and analytical sciences, development and regulatory requirements.
- Offering development, manufacturing and testing services for sterile pharmaceutical products.
- ten23 health will prioritize the health of patients, as well as the health of the planet and the well-being of its employees.
- The company is solidly financed through the long-term commitment by 3i Group, an internationally reputable equity partner.
ten23 health®, a new, globally operating contract development and manufacturing organization (CDMO), announced its launch today. The company will support biotech start-ups and established pharmaceutical customers in developing safe injectable biopharmaceutical drugs for patients.
ten23 health is led by a highly experienced team of experts, including CEO Prof. Dr Hanns-Christian Mahler, and senior leaders with a proven track record in the field of pharmaceutical product design and development and with an extensive global pharma network. ten23 health is uniquely positioned to provide holistic design and development services with its differentiated pharmaceutical and application knowhow. ten23 health’s offering includes a development roadmap, de-risking strategies and throughout support in its execution.
ten23 health is also differentiated by its distinct vision of making a positive impact for people and the planet. The company will aim for a net zero emissions target from its inception, exhibiting its patient-centricity not only in the quality of service that it delivers, but also in its sustainability focus.
Comprehensive offering driven by holistic thinking
Prof. Dr. Hanns-Christian Mahler, Chief Enabling Officer (CEO) of ten23 health, commented: «There is a significant unmet need in the life sciences market. The number and complexity of molecules and novel therapeutic modalities are increasing. Medical research is facing growing challenges with respect to the stability, usability, and consistent manufacturing of medicines.» He adds: «Our comprehensive offering will allow our clients to focus on the medicine and the patient, whilst leveraging our pharmaceutical expertise and knowledge to plan and de-risk product development to enable commercialization with speed, quality, and success. Our partners will benefit from shorter development timelines, higher probability of technical success, and ultimately stronger market positioning as a result.»
Richard Relyea, Partner at 3i and member of ten23 health’s Board of Directors, commented: «ten23 health stands out by providing world-class pharmaceutical and application knowhow with a holistic thinking that goes much further than pure execution and a transactional mentality. We will deliver services in an engrained, fair and sustainable manner, respecting the future of the planet and people’s health. With our investment in ten23 health, we aim to support the establishment of a uniquely differentiated partner to leading global biotech and pharmaceutical customers in the development, manufacturing and testing of complex and effective injectable biopharmaceutical drugs.»
Headquartered in Basel, Switzerland - one of the most vibrant life sciences clusters
ten23 health started its operative business on the Rosental campus “Rosental Mitte” in Basel, Switzerland per August 1 2021, taking over a fully operational lab and office building from Elanco. The building includes around 4,000 square meters of lab and office space, and will provide a work environment for 150 FTEs. Benefiting from the talented workforce in the Basel area, ten23 health has hired a team of accomplished leaders, scientists and technicians.
Kaspar Sutter, member of the Government of the Canton of Basel-Stadt and Head of the Department of Economic, Social and Environmental Affairs, commented: «The launch of ten23 health has a positive impact on our dynamic life sciences cluster by creating highly qualified jobs, leveraging local networks and adding to the increasing diversity of pharmaceutical and biotech companies and their strategic partners in our tri-national region.»
Highly experienced Leadership Team
The company is led by a very experienced team with a proven track record in the field of pharmaceutical product design and development and with an extensive global pharma network.
Chief Enabling Officer (CEO) is Prof. Dr. Hanns-Christian Mahler, who was the former Head of Drug Product Services at Lonza. Previous roles have been: Head of Pharmaceutical Development & Supplies at Roche and Principal Scientist at Merck KGaA. Mahler is also a Lecturer for Pharmaceutical Biotechnology at the University of Basel and the University of Frankfurt/Main, Editor for various scientific journals at Springer Nature and Elsevier, and appointed expert by the European Pharmacoepeial commission (EDQM, Strasbourg).
